2026 Immune Response Small Molecule Therapies 
Drug Discovery World
SEPTEMBER 6, 2022
DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.
Expert insights. Personalized for you.
130 
Let's personalize your content